Primary vitreoretinal lymphoma (PVRL) is a malignant large B-cell lymphoma affecting the eye and brain, with 5-year cumulative survival rate of 35% in those with brain involvement (68% in those without).1 Ocular involvement manifests with aggregated tumor cells in the vitreous, retina, optic disc, and subretinal pigment epithelial space. Management involves treatment of both eyes and brain, and treatment options for the eye(s) include systemic chemotherapy, external radiotherapy, or intravitreal injection of chemotherapy.
Shields CL, Sioufi K, Mashayekhi A, Shields JA. Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug. JAMA Ophthalmol. 2017;135(7):815–818. doi:10.1001/jamaophthalmol.2017.1810
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.